💡 Market Insight - GOOGL Stock Tracking
This article provides a brief overview related to $GOOGL, a prominent stock, highlighting where relevant discussions and information might be found.
Key Points:
• Financial symbols like $GOOGL allow for tracking specific company stock performance.
• Social media platforms facilitate real-time discussion and sentiment analysis for stocks.
• Visual aids often accompany market discussions to illustrate trends or data.
🔗 Resources:
• VibeCoderMcSwag Profile ↗ - VibeCoderMcSwag's X profile
• Mindset4Money_X Profile ↗ - Mindset4Money_X's X profile
• Mindset4Money_X Tweet ↗ - Specific tweet by Mindset4Money_X
• X Search for $GOOGL ↗ - Search results for $GOOGL on X
• OpenAI Photo ↗ - Photo from an OpenAI tweet
Image
Image
🤖 Letta Code - Memory-First Coding Agent
This article introduces Letta Code, an open-source coding agent designed with a memory-first approach, emphasizing its core features and capabilities.
Key Points:
• Letta Code functions as a memory-first coding agent.
• It is an open-source project under the Apache 2.0 license.
• The agent is model agnostic, allowing flexibility with various AI models.
• It features portable agent learning and memory for adaptable development.
🔗 Resources:
• VibeCoderMcSwag Profile ↗ - VibeCoderMcSwag's X profile
• Letta AI Profile ↗ - Letta AI's X profile
• Letta Code Release Tweet ↗ - Specific announcement tweet about Letta Code
✨ Medivis - AR Cranial Navigation FDA Clearance
This article announces Medivis's FDA 510(k) clearance for its Cranial Navigation platform, highlighting its significance as the first AR system cleared for intraoperative neurosurgery guidance.
Key Points:
• Medivis achieved FDA 510(k) clearance for its Cranial Navigation platform.
• It is the first AR system globally cleared for intraoperative neurosurgery guidance.
• The technology provides real-time, AR-guided visualization during procedures.
• This clearance marks a significant milestone in medical technology advancement.
🔗 Resources:
• Medivis AI Profile ↗ - Medivis AI's X profile
• FDA Clearance Announcement ↗ - Specific announcement tweet by Medivis_AI
Image
Image
💡 Medivis - Further Information on AR Navigation
This article provides additional resources for those seeking more information regarding Medivis's FDA-cleared AR Cranial Navigation platform and related developments.
Key Points:
• Further details about Medivis's advancements are available through provided resources.
• Information includes general company updates and specific platform details.
• Accessible links direct users to official announcements and related content.
🔗 Resources:
• Medivis AI Profile ↗ - Medivis AI's X profile
• Medivis Follow-up Tweet ↗ - Specific follow-up tweet by Medivis_AI
• Medivis Official Information ↗ - Official article or page for more details
💡 TechBio Talks - Real-World Data in Healthcare
This article highlights the latest episode of the TechBio Talks podcast, featuring a discussion with Dr. Amy Abernethy on the transformative impact of structured, real-world data in healthcare and medicine.
Key Points:
• The TechBio Talks podcast explores the impact of real-world data in healthcare.
• Dr. Amy Abernethy discusses data transformation in medicine.
• Structured, analyzable data is revolutionizing healthcare practices.
• The episode features insights from a physician, innovator, and executive.
🔗 Resources:
• Recursion Pharma Profile ↗ - Recursion Pharma's X profile
• Podcast Announcement Tweet ↗ - Specific podcast announcement tweet
Image
✨ Oncology - T-DXd + Pertuzumab Approval
This article details the FDA approval of T-DXd + Pertuzumab for 1L metastatic Her2+ breast cancer, based on results from the #DestinyBreast09 study, comparing its efficacy and safety against THP.
Key Points:
• T-DXd + Pertuzumab received FDA approval for 1L metastatic Her2+ breast cancer.
• The approval is supported by data from the #DestinyBreast09 trial.
• Median PFS showed significant improvement (40.7 vs 26.9 months) compared to THP.
• Complete response rates were higher (15.2% vs 8.5%) with T-DXd + Pertuzumab.
• Serious treatment-emergent adverse events and interstitial lung disease incidences are noted.
🔗 Resources:
• KolPulseAI Profile ↗ - KolPulseAI's X profile
• OncBrothers Profile ↗ - OncBrothers' X profile
• FDA Approval Announcement ↗ - Specific approval announcement tweet
• U.S. FDA Profile ↗ - U.S. FDA's X profile
• DestinyBreast09 Hashtag ↗ - Hashtag for DestinyBreast09 trial
• OncTwitter Hashtag ↗ - Hashtag for oncology discussions on X
• BCSM Hashtag ↗ - Hashtag for breast cancer social media
• OncoAlert Profile ↗ - OncoAlert's X profile
• OncUpdates Profile ↗ - OncUpdates' X profile
Image
Image
Image
Image
✨ Oncology - Confirmation of T-DXd+P Approval
This article provides a brief confirmation and positive reaction regarding the approval of T-DXd+P for first-line metastatic HER2+ breast cancer, referencing the DB09 study.
Key Points:
• T-DXd+P has been approved for 1L metastatic HER2+ breast cancer.
• The approval is based on results from the DB09 study.
• This marks a positive development in breast cancer treatment.
🔗 Resources:
• KolPulseAI Profile ↗ - KolPulseAI's X profile
• Stolaney1 Profile ↗ - Stolaney1's X profile
• Confirmation Tweet ↗ - Specific confirmation tweet by Stolaney1
• OncoAlert Profile ↗ - OncoAlert's X profile
• DFCI Breast Oncology Profile ↗ - Dana-Farber Cancer Institute Breast Oncology's X profile
🤖 Neuroscience - EEG for Parkinson's Characterization
This article discusses research exploring the utility of resting-state EEG, specifically using the Enobio device, to characterize Parkinson's disease by examining alpha asymmetry and its associations with various symptoms and disease progression.
Key Points:
• Resting-state EEG can help characterize Parkinson's disease.
• Researchers used the Enobio device to examine alpha asymmetry in patients.
• Associations were found between EEG alpha asymmetry and gait/balance issues.
• Links were identified with rest tremor, freezing, attention, and disease progression.
🔗 Resources:
• Neuroelectrics Profile ↗ - Neuroelectrics' X profile
• Research Announcement Tweet ↗ - Specific research announcement tweet
• EEG Hashtag ↗ - Hashtag for Electroencephalography
• Parkinson's Hashtag ↗ - Hashtag for Parkinson's disease
• Enobio Hashtag ↗ - Hashtag for Enobio device
• Full Study Link ↗ - Full scientific study on EEG in Parkinson's
Image
💡 Cancer Research - Top Institutes on X during SABCS
This article presents insights into the top cancer institutes active on X during the San Antonio Breast Cancer Symposium (SABCS) 2025, based on oncologist engagement and views.
Key Points:
• Insights reveal top cancer institutes' engagement on X during SABCS 2025.
• Ranking is based on oncologists' posts and views.
• Further data and insights from #SABCS25 are available.
• LARVOL provides oncology insights and cancer data analysis.
🔗 Resources:
• Larvol Profile ↗ - Larvol's X profile
• SABCS Insights Announcement ↗ - Specific announcement tweet
• SABCS San Antonio Profile ↗ - SABCS San Antonio's X profile
• SABCS25 Insights Page ↗ - Insights and data from SABCS25
• SABCS25 Hashtag ↗ - Hashtag for SABCS 2025 conference
• LARVOL Hashtag ↗ - Hashtag for LARVOL insights
• SABCS2025 Hashtag ↗ - Hashtag for SABCS 2025 conference
• Oncology Hashtag ↗ - Hashtag for oncology topics
• CancerResearch Hashtag ↗ - Hashtag for cancer research
• CancerData Hashtag ↗ - Hashtag for cancer data
• Oncologylnsights Hashtag ↗ - Hashtag for oncology insights
• BreastCancer Hashtag ↗ - Hashtag for breast cancer
• BCSM Hashtag ↗ - Hashtag for breast cancer social media
• Dana-Farber Profile ↗ - Dana-Farber's X profile
Image
💡 Healthcare Policy - Diversity in FDA Drug Trials
This article discusses the concerning lack of racial and ethnic diversity in FDA drug approval trials, noting that only 6% reflect U.S. diversity, with declining participation from Black and Hispanic communities since 2021.
Key Points:
• Only 6% of FDA drug approval trials reflect U.S. racial and ethnic diversity.
• Participation from Black and Hispanic communities has declined since 2021.
• This trend raises significant concerns for equitable precision medicine.
• The issue impacts the applicability and effectiveness of treatments across diverse populations.
🔗 Resources:
• Medical Xpress Profile ↗ - Medical Xpress's X profile
• Diversity in Trials Tweet ↗ - Specific article announcement tweet
• Only Hashtag ↗ - Hashtag from the original tweet
• UC Riverside Profile ↗ - UC Riverside's X profile
• Nature Portfolio Profile ↗ - Nature Portfolio's X profile
• Medical Xpress Article ↗ - Article on drug trials diversity
• Study DOI Link ↗ - DOI link for the related study
⭐️ Support
If you liked reading this report, please star ⭐️ this repository and follow me on Github ↗, 𝕏 (previously known as Twitter) ↗ to help others discover these resources and regular updates.
